Syndax Pharmaceuticals SNDX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's total equity?
- Syndax Pharmaceuticals (SNDX) reported total equity of $41.62M in Q1 2026.
- How has Syndax Pharmaceuticals's total equity changed year-over-year?
- Syndax Pharmaceuticals's total equity decreased by 80.6% year-over-year, from $215.06M to $41.62M.
- What is the long-term trend for Syndax Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total equity has grown at a -23.8% compound annual growth rate (CAGR), from $252.19M to $64.63M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.